Photo Credit: Md Saiful Islam Khan
The following is a summary of “Association Between the Serum Level of Asprosin and Metabolic Parameters in Adult Growth Hormone Deficiency: A Cross-Sectional Study,” published in the November 2024 issue of Endocrinology by Yang et al.
People with adult growth hormone deficiency (AGHD) often experience central obesity and metabolic disorders, including dyslipidemia and insulin resistance.
Researchers conducted a retrospective study to examine the relationship between serum asprosin levels and metabolic parameters in people with AGHD.
They enrolled 40 male participants with AGHD (mean age: 33.5 ± 9.5 years, BMI: 25.0 ± 4.5 kg/m2) and 40 controls matched by age, gender, and BMI. Medical, anthropometric, biochemical, and hormonal data were collected. Fat mass, fat percentage, and fat-free mass (FFM) were assessed using bioelectrical impedance, and serum asprosin levels were measured by ELISA.
The results showed that people with AGHD had significantly higher waist-to-hip ratios, triglyceride levels, and lower high-density lipoprotein (HDL)-cholesterol levels compared to controls. Additionally, people with AGHD had substantially higher serum asprosin levels (P=0.039). A strong association was found between serum asprosin levels, FFM, triglycerides, and HDL cholesterol in the entire study population.
They concluded that elevated serum asprosin levels were associated with metabolic alterations in people with AGHD, which could help identify biomarkers for metabolic syndrome risk in the population.
Source: onlinelibrary.wiley.com/doi/full/10.1155/ije/9735508
